KEY TAKEAWAYS
- Phase 3 RATIONALE-307 trial evaluated the impact of tislelizumab in combination with chemotherapy on HRQoL in sq-NSCLC patients.
- The study primarily aimed to assess the effect of incorporating tislelizumab into standard chemotherapy on HRQoL using the EORTC QLQ-C30 and QLQ-LC13 questionnaires.
- The study randomized participants into three groups: Arm A, tislelizumab + carboplatin + paclitaxel; Arm B, tislelizumab + carboplatin + nab-paclitaxel; and Arm C, carboplatin + paclitaxel.
- The study found that Arms A and B improved GHS/QoL scores and decreased lung cancer-specific symptoms compared to Arm C.
- Tislelizumab combo shows a favorable risk-benefit ratio for sq-NSCLC treatment.
The study evaluated the impact of incorporating tislelizumab into the initial standard-of-care chemotherapy regimen on the health-related quality of life (HRQoL) of individuals diagnosed with advanced squamous non-small cell lung cancer (sq-NSCLC). The subjects enrolled in the open-label, multicenter, phase 3 RATIONALE 307 study were randomized into three groups: Arm A, which received tislelizumab in combination with carboplatin and paclitaxel; Arm B, which received tislelizumab in combination with carboplatin and nab-paclitaxel; and Arm C, which received paclitaxel plus carboplatin. The patient’s Health-Related Quality of Life (HRQoL) was assessed through the utilization of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the EORTC Quality of Life Questionnaire Lung Cancer 13-item module (QLQ-LC13). The study analyzed the mean score variation from baseline at Weeks 6 and 12 in the global health status/quality of life (GHS/QoL), fatigue, and physical functioning scores of the QLQ-C30 questionnaire the lung cancer-specific subscales of the QLQ-LC13. The GHS/QoL score was assessed for the estimated time of deterioration.
A cohort of 355 patients with stage non-small cell lung cancer (sq-NSCLC) were administered the study medication and underwent at least one assessment of the health-related quality of life (HRQoL). The Global Health Status/Quality of Life scores exhibited improvement in Arms A and B compared to Arm C during Weeks 6 and 12. Arms A and B exhibited a decrease in the majority of lung cancer-specific symptoms in comparison to Arm C. The deterioration of Global Health Status/Quality of Life was achieved in all three treatment groups. The incorporation of tislelizumab in conjunction with platinum-based chemotherapy has been linked to enhancements in the health-related quality of life (HRQoL) of patients with squamous non-small cell lung cancer (sq-NSCLC), particularly in the domains of global health status/quality of life (GHS/QoL). Additionally, it has demonstrated significant improvements in lung cancer-specific symptoms such as coughing, dyspnea, and hemoptysis, which are of utmost importance.
Source: https://www.sciencedirect.com/science/article/pii/S2468294221001970?via%3Dihub#tbl0001
Clinical Trail: https://clinicaltrials.gov/ct2/show/NCT03594747
J Wang, X Yu, G Barnes, S Leaw, Y Bao, B Tang/The effects of tislelizumab plus chemotherapy as the first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial/Cancer Treatment and Research Communications, 30, 100501. https://doi.org/10.1016/j.ctarc.2021.100501
